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Abstract
Objectives: To evaluate the results of salvage conformal radiation therapy (3DC-EBRT) for
patients submitted to radical prostatectomy (RP) who have achieved complete PSA response and
who have never been treated with hormonal therapy (HT).
To present the results of biochemical control, a period free from hormonal therapy and factors
related to its prognosis.
Materials and methods: from August 2002 to December 2004, 43 prostate cancer patients
submitted to RP presented biochemical failure after achieving a PSA < 0.2 ng/ml. They have never
received HT and were submitted to salvage 3DC-EBRT. Median age was 62 years, median
preoperative PSA was 8.8 ng/ml, median Gleason Score was 7. Any PSA rise above 0.2 was defined
as biochemical failure after surgery. Median 3DC-EBRT dose was 70 Gy, biochemical failure after
EBRT was defined as 3 consecutive rises in PSA or a single rise enough to trigger HT.
Results: 3-year biochemical non-evidence of disease (BNED) was 71%. PSA doubling time lower
than 4 months (p = 0.01) and time from recurrence to salvage EBRT (p = 0.04) were associated
with worse chance of biochemical control. Biochemical control of 76% was achieved when RT had
been introduced with a PSA lower than 1 ng/ml vs. 48% with a PSA higher than 1 (p = 0.19). Late
toxicity was acceptable.
Conclusion: 70% of biochemical control in 3 years can be achieved with salvage radiotherapy in
selected patients. The importance of PSADT was confirmed in this study and radiotherapy should
be started as early as possible. Longer follow up is necessary, but it is possible to conclude that a
long interval free from hormonal therapy was achieved with low rate of toxicity avoiding or at least
delaying several important adverse effects related to hormonal treatment.
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Background
Radical prostatectomy (RP) is an efficient method of
achieving prostate cancer control. The follow-up is based
on clinical history, physical exams and following the Pros-
tate Specific Antigen (PSA) kinetics. Of the patients who
fail to achieve biochemical control, the principle of select-
ing the best salvage therapy is based upon determining
whether the disease is still on the prostate bed or if it has
already spread throughout the body. Several studies are
aiming at determining which variables correlate with a
higher chance of detecting localized recurrences. In these
cases, adopt a potentially curative salvage therapy (radio-
therapy) instead of hormonal therapy alone.
The problem with many of these studies is that they usu-
ally include a broad group of patients who have never
reached an indetectable PSA or those who have been pre-
viously treated with some sort of hormonal therapy mak-
ing assessment using PSA difficult to evaluate.
The objective of this study is to evaluate the results of bio-
chemical control and to analyze a period free from hor-
monal therapy after salvage radiation therapy in a selected
group of patients who have never been treated before with
hormonal therapy and have achieved complete PSA
response after RP.
The secondary objectives are to evaluate prognostic factors
related to the success of the salvage radiation therapy.
Materials and methods
Patients
From August 2002 to December 2004, 79 prostate cancer
patients previously treated with radical prostatectomy
(RP) were submitted to salvage three-dimensional confor-
mal external beam radiation therapy (3DC-EBRT) due to
biochemical failure. Thirty-six patients were excluded
from the analysis: those who have not achieved PSA nadir
(<0.2 ng/ml) after RP or those who were submitted to hor-
monal therapy before or during salvage radiation. Forty
three patients were eligible. The median age was 62 years
(range 50–73) and Caucasians were predominant
(88.4%). Patients and treatment characteristics are show
in Table 1.
Preoperative characteristics
Six patients (14%) were cT1c, 3 (7%) were cT2a, 2 (4.7%)
were cT2b, 1 (2.3%) was cT2c. In 31 patients (72.1%) pre-
operative staging was not available. Median pre-operative
PSA was 8.8 ng/ml (range 3 – 62) and hormonal therapy
was not administered to any of then prior to surgery.
Twenty-eight patients (65%) had information on the
biopsy specimen, the median Gleason score was 6 (range
4 – 8).
Biochemical recurrence
We defined biochemical recurrence after surgery as a sin-
gle PSA value greater than 0.2 ng/ml after surgery in men
with no evidence of distant metastasis at the time of radi-
otherapy.
After salvage radiotherapy, biochemical failure was based
on the ASTRO (American Society of Therapeutic Radia-
tion Oncology) criteria as three consecutive PSA rises or a
single rise was high enough to trigger the initiation of hor-
mone therapy.
Postoperative characteristics
In surgical staging according to 2002 AJCC staging system,
11 patients (25.6%) were pT2a; 3 patients (7%) were
pT2b; 7 (16.3%) were pT2c; 21 (48.8%) were pT3a and
only 1 patient (2.3%) was pT3b. The median Gleason
score was 7 (range 4 – 8). Surgical margin was affected in
23 patients (53.5%). Perineural invasion (PNI) was found
in 30 patients (69.8%); There was no information regard-
ing PNI, Lymphatic invasion (LI), Vascular invasion (VI)
and intraepithelial neoplasia (PIN) in respectively 16.3%,
28%, 30.2% and 58% (Table 1).
After surgery the median interval to failure was 12 months
(range 2 – 39). Median PSA before salvage radiotherapy
was 0.87 ng/ml (range 0.24 – 7.9). PSA doubling time
(PSADT) was calculated for each patient based on loga-
rithmic regression formula and we used at least 2 PSA val-
ues separated by 2 months in the 18 months before
salvage radiation.
At the time of recurrence all patients were submitted to
physical examination which included a digital rectal
exam, chest radiography, whole body bone scan and a
trans-rectal pelvic ultrasonography. Eleven patients
(25.6%) presented a nodule in the prostatic bed.
Radiotherapy
Patients were submitted to external beam radiation ther-
apy with a 10 MV linear accelerator (CLINAC 2100 – Var-
ian®) using conformal three-dimensional technique. All
patients were submitted to a pre-planning set up in a sim-
ulator (Acuity – Varian®) with retrograde urethrogram to
help define the isocenter. A pelvic computed tomography
(CT) was then performed to delinement of planning tar-
get volume. Twenty patients (46.6%) were treated with 2
planning tumor volumes (PTV): PTV1 included the surgi-
cal prostate bed and seminal vesicles bed with margins
and the PVT2 included only the surgical prostate bed with
margin. This technique was used according to the attend-
ing physician preferences based on post-surgical patho-
logical information and pre treatment prostate image
characteristics. Nineteen out of 20 patients treated this
way had T3 tumors. Median dose to PTV1 was 50.4 GyRadiation Oncology 2007, 2:8 http://www.ro-journal.com/content/2/1/8
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Table 1: Patients' characteristics
N%
Clinical Stage:
T1c 61 4
T2a 37
T2b 24 . 7
T2c 12 . 3
Unknown 31 72
Preoperative PSA:
<10 ng/ml 24 55.80
10–20 ng/ml 9 21.0
>20 81 8 . 6 0
Unknown 2 4.6
Preoperative Gleason Score:
<6 10 23.2
.6 12 27.9
>6 6 13.9
unknown 15 34.9
Pathological Stage:
pT2a 11 25.6
pT2b 3 7
pT2c 7 16.3
pT3a 21 48.8
pT3b 1 2.3
Postoperative Gleason Score:
<6 7 16.3
.6 13 30.2
>6 23 53.5
Surgical margins:
Compromised 23 53.5
Clear 20 46.5
PNI:
Yes 30 69.7
No 61 4
Unknown 7 16.3
LVI:
Yes 61 4
No 25 58
Unknown 12 28
BVI:
Yes 37
No 27 62.8
Unknown 13 30.2
PIN:
Yes 11 25.6
No 7 16.3
Unknown 25 58
Total: 43 100
PNI, perineural invasion; LVI, Limphovascular space invasion,
BVI, blood vascular space invasion; PIN, prostatic intraepithelial neoplasiaRadiation Oncology 2007, 2:8 http://www.ro-journal.com/content/2/1/8
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(range 46 – 54) and for all patients median dose to the
prostate bed was 70 Gy (range 66 – 72). Median dose per
fraction was 2 Gy (range 1.8 – 2).
Follow-up
PSA was ordered every 3 months in the first year, every 4
months in the second year and yearly thereafter. Digital
rectal examination was performed twice yearly.
Statistical Analyses
Variables were evaluated using the chi-square test. Kaplan-
Meier test was used to calculate overall and specific sur-
vival. Univariate analysis was assessed using the log-rank-
test and Multivariate analysis was performed by Cox
regression.
Morbidity
Complications were recorded for genitourinary and gas-
trointestinal side effects. All acute and late complications
were scored according to the Radiation Therapy Oncology
Group (RTOG) scale.
Results
Median interval from RP to biochemical failure was 12
months (range 2 – 39) and median time after failure to
salvage 3DC-EBRT was 8 months (range 1 – 52). The
median follow-up after radiotherapy was 26 months
(range 8 – 41). One (1) patient (2.3%) was lost to follow-
up. At the end of data collection no patients had died. Dis-
tant metastasis developed in 2 (4.7%) patients and 33
patients (76.7%) were free from biochemical failure. Of
these, 28 patients (85%) developed undetectable PSA
(<0.1 ng/ml) after a median interval of 3 months (range 1
– 30). Actuarial Biochemical Non-Evidence of Disease
(BNED) at 3 years was 70.71% (Figure 1).
Median PSA pre-radiation was 0.87 ng/ml (range 0.21 –
7.9) and median PSADT was 5.25 months (range 1.0 –
16.5). Univariate and multivariate analysis of selected var-
iables are displayed on Table 2.
PSADT lower than 4 months was an important negative
prognostic factor to BNED/3-years (48.4% vs 75.6%, p =
0.012 – Figure 2). Delaying radiation therapy after bio-
chemical recurrence for more than 3 months was associ-
ated with worse BNED/3-years (60% vs 100%, p = 0.04 –
Figure 3). BNED/3-years for patients with PSA pre radia-
tion higher than 1 ng/ml was 48.13% versus 75.9% for
patients with lower PSA levels before radiation although it
did not reach statistical significance (p = 0.19). Patients
with clinical or radiological evidence of a macroscopic
tumor on surgical bed showed BNED/3-years of 80.81%
versus 66.5% for patients without evidence of local dis-
ease. Again, it did not reach statistic significance (p=
0.44).
Interval from surgery to biochemical failure, Gleason
score, extracapsular extension, lymphovascular invasion,
perineural extension or surgical margin involvement were
not associated with prognosis.
BNED/3-years for patients submitted to radiotherapy
including seminal vesicle bed was 81.64% versus 61.5%
for patients submitted to radiotherapy to prostatic bed
only without reaching statistical significance (p = 0.2).
Total dose to surgical bed higher than 66 Gy did not result
in better BNED/3-years (p = 0.6).
By multivariate analysis only a PSADT lower than 4
months was a negative predictive factor for BNED/3-years
(p = 0.01; CI 95% – Table 3).
According to the RTOG morbidity scale 6 patients pre-
sented grade 3 late genitourinary effects (14.6%) and 1
patient (2.3%) presented grade 3 late gastrointestinal tox-
icity. No grade 4, acute or chronic, toxicity was seen. Table
3 shows the crude incidence of gastrointestinal and geni-
tourinary complications. Grade 3 genitourinary morbidity
was higher for patients who received radiotherapy for
seminal vesicle bed, but without statistical significance
(21 vs 8%, p = 0.38).
Discussion
Prostate cancer is an indolent disease and the best way to
evaluate disease control after radical treatment is monitor-
ing PSA. It is estimated that about 1/3 of patients with bio-
chemical failure following radical treatment will develop
distant metastasis in a period of 8 years [1], but it is not a
Biochemical control after salvage radiotherapy for patients  who have never received hormonal therapy after radical  prostatectomy Figure 1
Biochemical control after salvage radiotherapy for patients 
who have never received hormonal therapy after radical 
prostatectomy.Radiation Oncology 2007, 2:8 http://www.ro-journal.com/content/2/1/8
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Table 2: Uni and multivariate analysis
3-year BNED (%) Univariate analysis Multivariate analysis
Variable pp  ( C I 9 5 % )
Gleason Score
≤7 61 0.25 0.38
>7 78
Pathological Stage
≤pT3a 77 0.59 0.63
pT3a or pT3b 64
Surgical Margins
compromised 67 0.65 0.5
clear 74
PNLVSI
positive 68 0.31 0.29
negative 100
Time to recurrence after RP
≤12 meses 75 0.9 0.85
>12 meses 66
PSADT
≤4 meses 48.4 0.01 0.01
>4 meses 75.6
Preradiation PSA
≤1 ng/ml 75.9 0.1 0.7
>1 ng/ml 48.1
Time to radiation after recurrence
≤3 months 100 0.04 0.1
>3 months 60
Clinical tumor on surgical bed
Yes 80 0.4 0.46
No 66
Radiation dose (Gy)
≤66 Gy 76 0.62 0.7
>66 Gy 68
CI, confidence interval; PNLVSI, perineural or lymphatic or vascular space invasion; PSADT, PSA doubling time; Gy, Gray.Radiation Oncology 2007, 2:8 http://www.ro-journal.com/content/2/1/8
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consensus whether or not biochemical control will
improve survival [2].
After RP 70% of patients will achieve biochemical control
in 10 years [3-6]. However, the appropriated definition of
biochemical failure after surgery and PSA failure have
been defined by different authors as a PSA greater than
0.2, 0.3, 0.4 or 0.5 ng/ml after RP [1,7-9]. Only patients
with undetectable PSA after RP were included in the
present study and we defined biochemical failure after
surgery as any PSA value higher than 0.2 ng/ml.
Several variables have been described as prognostic factors
for failure after surgery: histological grade (Gleason
score); capsular or seminal vesicles extension; positive
lymph nodes and involvement of surgical margins [10-
12]. In our analysis 51% of patients had capsular involve-
ment; Gleason score higher than 6 was found in 53.5%
and margins were affected in 53.5%. No pathological
characteristics were related to biochemical control proba-
bly due the small number of patients and short follow up
of this cohort. However it is important to emphasize that
our data differ from other studies since we have selected
only patients who had indetectable PSA after surgery and
who had never been submitted to hormonal treatment.
Salvage radiotherapy after RP is the only potential curative
modality, but several published series have not demon-
strated uniform results of BNED (18 to 68%) [9,13-27].
The most important issue in patients with biochemical
failure is to define which patients will benefit from salvage
treatment to the prostate bed. Unfortunately, an increase
in PSA level after local treatment does not distinguish
local recurrence from distant metastasis. Usual image
exams or biopsy have not proved yet to be helpful in
Table 3: Crude incidence of gastrointestinal and genitourinary morbidity
Toxicity Grade 1 Grade 2 Grade 3 Grade 4
Gastrointestinal
Acute 8(19.4%) 4(10%) 1(2.3%) 0
Late 2(5%) 4(10%) 1(2.3%) 0
Genitourinary
Acute 6(15%) 4(10%) 1(2.3%) 0
Late 4(10%) 1(2.3%) 6(14.6%) 0
Biochemical control after salvage radiotherapy according to  PSADT (PSA doubling time) lower or higher than 4 months  for patients who have never received hormonal therapy after  radical prostatectomy Figure 2
Biochemical control after salvage radiotherapy according to 
PSADT (PSA doubling time) lower or higher than 4 months 
for patients who have never received hormonal therapy after 
radical prostatectomy.
Biochemical control after salvage radiotherapy according to  time to radiation after biochemical recurrence for patients  who have never received hormonal therapy after radical  prostatectomy Figure 3
Biochemical control after salvage radiotherapy according to 
time to radiation after biochemical recurrence for patients 
who have never received hormonal therapy after radical 
prostatectomy.Radiation Oncology 2007, 2:8 http://www.ro-journal.com/content/2/1/8
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defining anatomical site of biochemical recurrence
[21,28,29]. This fact could then explain the unfavorable
outcomes with salvage radiation described in several
series specially early published series [30]. Radioimmuno-
scintigraphy (RIS) is a new exam that could be helpful in
defining this issue as recently suggested by Jani. They have
presented promising results from a study with RIS and it
is possible that the RIS could impact decision making
[31].
In our experience BNED in 3 years was 71%, a result that
is compatible with results from other institutions
[9,16,22].
Although the follow-up is somewhat short for accurately
defining the effects of the salvage therapy on local control
or survival, another important result of the salvage radia-
tion treatment that should be considered is the effect on
the quality of life by delaying hormonal therapy. Hormo-
nal therapy has been shown to produce deleterious side
effects on the bone mass inducing higher chance of frac-
tures on the spine and bones that carry the body weight
[32].
The results of the present series of 70% BNED in 3 years
will probably reflect on the patients' quality of life
although we did not raise data to support such a conclu-
sion.
Lately, several published series have pointed out adverse
factors that could define patients with lower probability
of occult distant metastasis which might result in better
patient selection for local salvage treatment. The worst
prognostic factors related to salvage radiation up to this
moment are: higher Gleason score [9,15,16,18,24-26];
capsular or seminal vesicles extension [9,18,19,22,25,33];
free-surgical margins [9,33]; short PSADT [9,20,34-37]
and high preradiotherapy PSA level [13,15,16,18,20-
22,26,29]. Stephenson et al published recent results of the
largest retrospective series which pooled 501 patients of 5
institutions. Results from this study have confirmed the
negative prognostic value of high Gleason score (>7),
pathological staging (pT3b), short PSADT (<10 months)
and preradiation PSA level (>2 ng/ml) [9]. In our analysis
PSADT < 4 months was strongly correlated with lower
biochemical control (p = 0.01) reinforcing the importance
of PSA kinetics to the outcome. Gleason score, vascular
invasion, capsular extension and free surgical margin were
not related to BNED in the present study probably due to
the relatively small number of patients and the short fol-
low-up.
In a recent prospective trial from the European Organiza-
tion for Research and Treatment of Cancer (EORTC
22911), Bolla et al published results of a randomized
comparison of wait-and-see after RP or immediate post-
operative radiotherapy for high risk patients (pT3a, pT3b
or positive margin) and has shown that adjuvant radio-
therapy results in better progression free and local-
regional free survival [8]. In small retrospective series
[13,15,16,18,20-22,26] and in the series published by
Stephenson et al [9], patients with low preradiotherapy
PSA levels had better prognosis than those with high PSA.
Therefore the outcome is dictated by an earlier salvage
treatment. The ASTRO (American Society of Therapeutic
Radiation Oncology) consensus recommends salvage
radiation only for patients with PSA lesser than 1.5 ng/ml
[38]. In our experience BNED was better if patients were
submitted to salvage radiation earlier than 3 months after
biochemical recurrence (100 vs 60%, p = 0.04). The
BNED was also better if patients were treated before
achieving 1 ng/ml of PSA, however, without reaching sig-
nificance (75 versus 48%, p = 0.1))
We performed salvage treatment using conformal three-
dimensional radiotherapy with a median dose of 70 Gy
(range 66 – 72 Gy) and we have not found correlation
between radiation dose and BNED (p = 0.6). Small retro-
spective series suggest that conformal three-dimensional
radiotherapy and doses higher than 64,8 Gy do correlate
with better biochemical control [14,27], but it is definitely
not a consensus and it was also not demonstrated by
Stephenson et al (p = 0,24) [9]. ASTRO consensus suggests
doses higher than 64 Gy for salvage radiation setting [38].
If adjuvant radiotherapy is used lower radiation doses
may be sufficient [8].
There is no agreement regarding which volume should be
treated in prostatectomized patients. In the EORTC 22911
radiotherapy was delivered using 2 planning target vol-
umes. The first Planning Target Volume (PTV 1) was
defined by the anatomical limits of the surgical bed
including those of the seminal vesicles followed by a
boost in a reduced PTV (PTV2) to the prostate bed [8]. In
our experience similar treatment (with 2 PTVs) was
employed in 46% of patients. There was no difference in
biochemical control if patients were treated with 1 or 2
PTVs. This was probably due to the inclusion of the semi-
nal vesicle bed in patients treated with only one PTV. Jani
et al have demonstrated that the use of RIS to determine
to probable relapsed tumor could increase the PTV if com-
pared with CT based PTV and probably without great dif-
ference in toxicity, although more bladder volume could
receive doses higher than 60 Gy [39,40].
Some series have described low rates of complications
(RTOG > Grade 3) in patients submitted to salvage radio-
therapy, but what is generally postulated is that toxicity is
higher when radiotherapy is employed after surgery than
with exclusive radiotherapy specially in the genitourinaryRadiation Oncology 2007, 2:8 http://www.ro-journal.com/content/2/1/8
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tract [13,27]. Ascher et al have found only 3% of grade 3
or 4 late urinary toxicity [27]. Morris et al have described
a 6% incidence of grade 3 urethral stenosis after salvage
radiation and 5% after adjuvant radiotherapy [41]. Bolla
et al have shown lower late toxicity grade in patients sub-
mitted to adjuvant radiation than in patients submitted to
salvage radiation, although in adjuvant setting the dose
employed was lower (60 Gy) [8]. With a median dose of
70 Gy we found grade 3 urinary toxicity in 6 patients
(14%) and no late rectal toxicity. There was no difference
in morbidity whether radiotherapy was specifically
directed to seminal vesicle or if treatment was directed to
surgical bed only (p = 0.38).
Our data suggest that approximately 70% of biochemical
control in 3 years can be achieved with salvage radiother-
apy in selected patients and that 66 Gy may be sufficient
for disease control. The importance of PSADT was con-
firmed in our series and radiotherapy should be started as
early as possible. Longer follow up is necessary to confirm
these results, but at this moment it is possible to conclude
that a long interval free from hormonal therapy was
achieved with low rate of toxicity avoiding, or at least,
delaying several important adverse effects related to hor-
monal treatment.
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